Commercialization Committee

Name

Role

Tom PhilpottBio
Tom Philpott, Executive Director of Kids Brain Health Network (formerly NeuroDevNet), joins the Network from the Community for Excellence in Health Governance (CEHG), a national not-for-profit based in Nova Scotia that established to promote the sharing of best practices in governance. As Executive Director of CEHG, Tom’s work included initiating two international quality of care benchmarking projects and building a community-oriented web portal and learning management system. Tom spent eight years at the McGill University Health Centre (MUHC) as senior advisor in the Executive Office, as well as a program manager on the MUHC’s redevelopment project. In 2014 Tom consulted was a consultant to the Nova Scotia health system in strategy implementation, change management, and project management. He has significant volunteering experience, including lead judge for an international MBA case competition, United Way, and the McGill Faculty of Medicine Admissions Committee, among others. He has an MBA from the Richard Ivey School of Business (Western Ontario), MHA from uOttawa and BA in Political Science & History from McGill.
J.P. HealeMemberBio
J.P. Heale has worked at the University-Industry Liaison Office (UILO) at The University of British Columbia for the past thirteen years, most recently in the capacity of Associate Director, before being appointed Interim Managing Director in February 2014. He has overseen intellectual property management and licensing associated with UBC’s Affiliated Hospitals. Additional duties included oversight of sponsored research and clinical trial agreement negotiation and implementation. J.P. also manages external relations with such UBC-affiliated agencies as the Canadian Institutes for Health Research and the Centres of Excellence for Commercialization and Research. J.P. enjoys participating in the creation of spin-off companies based on University technologies, and was active in the formation of Indel Therapeutics, viDA Therapeutics, Boreal Genomics, Sirius Genomics, and ELIX Technologies which have raised over $40 million in private capital. J.P. graduated from UBC in 1997 with a doctorate from the Department of Biochemistry and Molecular Biology, and subsequently worked as a Post-Doctoral Fellow and Research Associate. J.P. received an MBA from Simon Fraser University in 2001 while working as Manager of Business Development at a UBC spin-off biotech company. In late 2001, J.P. joined the UILO in the Technology Transfer Group. The next year he became Technology Transfer Manager for the Children’s and Women’s Health Centre of BC, one of the affiliated hospital of UBC. J.P. took on the role of Associate Director in April 2004. J.P. is member of the Alliance for Commercialization of Canadian Technology (ACCT), the Association of University Technology Managers (AUTM), and Life Sciences. He is a grant reviewer for the CIHR Proof-of-Principle Committee, a member of the Research Advisory Council of Cystic Fibrosis Canada, the CECR PROOF Translation Advisory Committee, and Chairs the UBC Technology Equity Management Committee. He has previously been an observer on the boards of viDA Therapeutics Inc., Sirius Genomics Inc. and Boreal Genomics Inc. The UILO conducts the technology transfer and commercialization activities at UBC. UBC consistently ranks among the top ten North American universities for its patenting and commercialization activities. UBC currently has over 350 license and assignment agreements with companies around the world and has actively supported the creation of over 180 spin-off companies.
Tom CollinsMemberBio
Dr. Collins is the first president of The Sinneave Family Foundation and brings almost 40 years of experience in senior level positions in both the private and public sector to the Foundation. In addition to his role as president, Dr. Collins is a founding member of the consulting practice Stratavera Partners and the business advisory practice at Conroy Ross Partners. Previously, Dr. Collins served as senior vice-president with two Canadian Pacific Limited Companies, PanCanadian Petroleum and CP Ships. In 2001, Dr. Collins became integration coordinator for the merger that created Encana Energy, then the largest merger in Canadian business history.
Ryan D’ArcyMemberBio
Dr. D’Arcy uses non-invasive imaging techniques to learn more about the brain/behaviour relationship in healthy individuals and develop new diagnostic tests for neurological patients. He is Group Leader and Research Officer at the NRC's Institute for Biodiangostics (Atlantic), and Associate Professor of Radiology and Adjunct Professor of Neuroscience at Dalhousie University. Recent achievements include the opening of the Laboratory for Magnetoencephalography at the IWK Health Centre, which hosts Canada's most advanced 306 channel MEG system; the world's first virtual reality removal of a patient's brain tumour; and the introduction of the Halifax Consciousness Scanner.
Michael FehlingsMemberBio
Dr. Fehlings heads the Spinal Program at the Toronto Western Hospital. In addition, he is a Professor of Neurosurgery at the University of Toronto, holds the Halbert Chair in Neural Repair and Regeneration, is a Scientist at the McEwen Centre for Regenerative Medicine and a McLaughlin Scholar in Molecular Medicine. In the fall of 2008, Dr. Fehlings was appointed the inaugural Director of the University of Toronto Neuroscience Program (which he held until June 2012) and Co-Director of the newly formed University of Toronto Spinal Program. In 2014, Dr. Fehlings stepped down as Medical Director of the Krembil Neuroscience Centre, Toronto Western Hospital in order to accept the appointment of Vice Chair Research, Department of Surgery at the University of Toronto. His main clinical interests are in spinal neurosurgery, and his research focus is in molecular mechanisms underlying spinal cord injury as well as potential methods to repair the injured spinal cord and mitigate the injury. Research into Cerebral Palsy is a new and exciting direction of research for the Fehlings lab. His work in this area is currently focusing on remyelination.
Chris FibigerMemberBio
H. Christian Fibiger, Ph.D. received his B.Sc. in Chemistry and Psychology from the University of Victoria in 1966 and his Ph.D. in Psychopharmacology from Princeton University in 1970. Dr. Fibiger was formerly the Chief Scientific Officer for Biovail Laboratories International (now Valeant). From 2003 until 2007 he was Vice President and Global Head of Neuroscience at Amgen. In this position he was responsible for Amgen’s worldwide Neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. Before joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation, and LRL Europe at Eli Lilly and Company. Before moving to Lilly in 1998, Dr. Fibiger served as Professor and Head of the Division of Neurological Sciences and Chair of the University Graduate Program in Neuroscience at the University of British Columbia in Vancouver. He has made numerous contributions to neuroscience research and, during his academic career, was among the top 100 most cited scientists in neuroscience. He has received many honors for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a Fellow of the American College of Neuropsychopharmacology (ACNP). Dr. Fibiger serves on the editorial boards of several journals in the field of neuroscience and has been coeditor of Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology.
Anne FullerMemberBio

Information to come soon

David PhippsMemberBio
Dr. Phipps received his Ph.D. in Immunology from Queen’s University (Kingston, Ontario) and undertook post-doctoral studies in HIV research at the University Health Network (Toronto). After leaving the lab he built a career managing academic research holding successively senior positions at the University of Toronto Innovations Foundation (Manager of Biotechnology and Life Sciences), Canadian Arthritis Network (Director of Business Development) and Canadian Institutes of Health Research (Director of Partnerships). In 2001 Dr. Phipps completed his MBA from the Rotman School of Management (University of Toronto). Dr. Phipps is the Executive Director of Research & Innovation Services at York University where he manages all research grants and contracts including knowledge and technology transfer. In this capacity he leads York’s award winning Knowledge Mobilization Unit that provides services to researchers, community organizations and government agencies who wish to use maximize the economic, social and environmental impacts of university research. In 2011 and 2012 Dr. Phipps was named the most influential knowledge mobilizer in Canada and in 2012 York’s Knowledge Mobilization Unit was awarded a best practice award from the European-based Knowledge Economy Network. In 2012 he was awarded a Queen Elizabeth II Diamond Jubilee Medal in recognition of his work in knowledge mobilization. In 2013 he was one of three national finalists for the Impact Award – Connections category from the Social Sciences and Humanities Research Council of Canada. He also leads ResearchImpact-RéseauImpactRecherche, Canada’s knowledge mobilization network including 10 universities from across Canada.
Anneliese PoetzMemberBio
KT Core